Pacylex

Pacylex Presents Evidence Supporting Advancement of PCLX-001 for Treatment of AML at AACR 2022

New data on PCLX-001 being presented at AACR showing the potential for N-myristoylation inhibition to treat for AML with in vitro and animal model data: PCLX-001 dramatically reduces AML stem cells in the bone marrow.

Read More

Recent News

Pacylex

Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001 in Non-Hodgkin’s Lymphomas and Solid Tumor Patients

Read More

Pacylex

Pacylex featured as one of "Canada's 10 Most Valuable Healthcare Solution Providers" by Insightscare

Read More

Pacylex

Pacylex Presents Updates on the Journey of PCLX-001 to the Clinic at BIO and FASEB Conferences

Read More
Follow Pacylex